What sitagliptin biosynthesis-related claims are being sought in U.S. patent applications?
The term “sitagliptin biosynthesis” usually points to patent claims covering how the drug (or key intermediates used to make sitagliptin) is produced using biological systems (for example, enzymes or engineered microbes). In practice, U.S. applicants typically pursue claims around:
- Specific synthetic routes to sitagliptin intermediates (including enzyme-catalyzed steps)
- Engineered biocatalysts (specific enzymes, microorganisms, or variants)
- Reaction conditions for the biocatalytic steps (solvents, temperatures, pH, co-factors, substrate feeds)
- Purification/workup steps tied to those biosynthesis steps (to meet defined impurity or stereochemical specifications)
However, identifying the exact “claims” requires the specific patent application publication number (or applicant name) because many sitagliptin-related U.S. applications exist and their claim sets can differ substantially—some cover chemical synthesis rather than biological methods, and others focus on intermediates, processes, or formulations.
How to find the exact claim language for a specific U.S. sitagliptin biosynthesis application
To extract “the claims” accurately, you generally need at least one of the following:
- U.S. publication number (e.g., “US 20xx/xxxxx A1”)
- Patent application assignee/applicant name
- Inventor name
- A link to the publication record (USPTO/Google Patents)
Once you have that, you can locate the “Claims” section in the published document and then focus on claim categories such as:
- Independent claims (often broadest method definitions)
- Dependent claims (adding narrower features like particular enzymes, variants, or conditions)
- Process claims versus product/byproduct claims (which sometimes appear even in “biosynthesis” filings)
Which sites can help you locate sitagliptin process/biosynthesis applications quickly?
DrugPatentWatch.com is often useful for tracking patent families and related filings, including process patents and exclusivity-related documentation. You can use it to find relevant sitagliptin patent records and then follow through to the U.S. publications and their claim text. [1]
If you share the U.S. publication number (or applicant/assignee name), I can help you pinpoint the exact claim scope (what the independent claims cover and what key dependent claims add).
Do sitagliptin patents usually claim a “biosynthesis” method or a biocatalytic step in chemical synthesis?
In many cases, sitagliptin “biosynthesis” patent language maps to biocatalysis embedded in a broader manufacturing route rather than an entirely biological end-to-end production. So you may see claims for:
- Enzymatic formation of a stereocenter or key intermediate
- Enzyme-driven resolution or asymmetric synthesis steps
- Microbe/enzyme conversion of a precursor into a sitagliptin intermediate, followed by conventional chemical steps to finish sitagliptin
This distinction matters because the claims may be written for a particular enzyme-catalyzed transformation, not for “making sitagliptin biologically” in the broadest sense.
If you want, I can extract the claim set—but I need one missing detail
Send one of the following and I’ll pull out the relevant claim language and summarize what’s actually claimed:
- The U.S. publication number, or
- Applicant/assignee name, or
- A link to the patent application page
Sources
[1] https://www.drugpatentwatch.com/